The authors are saddened to report the death of our colleague and co-author Don Lewis shortly before this paper was submitted.
1526-4610/asset/olbannerleft.gif?v=1&s=21f1b7d4f2c4359aaf47df570ce3e86bae828611)
1526-4610/asset/olbannerright.gif?v=1&s=457ac636b692c34a480c656754b5858bd52359be)
Research Submission
You have free access to this content
Long-Term Open-Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs
Article first published online: 18 OCT 2012
DOI: 10.1111/j.1526-4610.2012.02285.x
© 2012 American Headache Society
Additional Information
How to Cite
Hewitt, D. J., Pearlman, E., Hämäläinen, M., Lewis, D., Connor, K. M., Michelson, D., Ceesay, P., Assaid, C., Bachman, R., Harper Mozley, L., Dupre, N., Strickler, N., Mahoney, E., Lines, C. and Ho, T. W. (2013), Long-Term Open-Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs. Headache: The Journal of Head and Face Pain, 53: 104–117. doi: 10.1111/j.1526-4610.2012.02285.x
Conflicts of Interest: This study was funded by Merck Sharp & Dohme Corp. David J. Hewitt, Kathryn Connor, David Michelson, Paulette Ceesay, Christopher Assaid, Robert Bachman, Lyn Harper Mozley, Nicole Dupre, Nancy Strickler, Erin Mahoney, Christopher Lines, and Tony W. Ho are current or former employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., and own stock/stock options in Merck. Eric Pearlman, Mirja Hämäläinen, and Donald Lewis have received consulting fees from Merck.
- †
The authors are saddened to report the death of our colleague and co-author Don Lewis shortly before this paper was submitted.
Trial Registration: ClinicalTrials.gov NCT01004263.
Publication History
- Issue published online: 8 JAN 2013
- Article first published online: 18 OCT 2012
- Manuscript Accepted: 7 AUG 2012
Funded by
- Merck Sharp & Dohme Corp
References
- 1, , , . Prevalence of headache and migraine in children and adolescents: A systematic review of population-based studies. Dev Med Child Neurol. 2010;52:1088-1097.
- 2, , , et al. Prevalence of headache and its association with sleep disorders in children. Pediatr Neurol. 2007;36:146-151.
- 3, , , , , ; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349.
- 4, , , , . Sumatriptan nasal spray in adolescent migraineurs: A randomized, double-blind, placebo-controlled, acute study. Headache. 2006;46:212-222.
- 5, , , , , . Efficacy and tolerability of almotriptan in adolescents: A randomized, double-blind, placebo-controlled trial. Headache. 2008;48:1326-1336.
- 6, , , et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel enrichment design. Cephalalgia. 2012;32:750-765.
- 7, , , . A randomized trial of rizatriptan in migraine attacks in children. Neurology. 2006;67:1135-1140.
- 8, , , et al. Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. Headache. 2012;52:625-635.
- 9, Jr, , et al. Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: An open-label, randomized, single-dose, 3-period crossover study. J Clin Pharmacol. 2006;46:172-178.
- 10, , , , , ; Rizatriptan Adolescent Study Group. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: A randomized, double-blind, placebo-controlled study. Headache. 2002;42:49-55.
- 11, , , et al.; Rizatriptan Protocol 059 and 061 Study Groups. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: Results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache. 2004;44:891-899.
- 12Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edn. Cephalalgia. 2004;24:9-160.
- 13, , . Measurement of pain in children with self-reporting and behavioral assessment. Clin Pharmacol Ther. 1987;42:137-141.
- 14, , , . Migraine and suicidal ideation in adolescents aged 13 to 15 years. Neurology. 2009;72:1146-1152.
- 15, , , . The prevalence of suicidal phenomena in adolescents: A systematic review of population-based studies. Suicide Life Threat Behav. 2005;35:239-250.
- 16, , , , . Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups. Headache. 1998;38:764-771.
- 17